Sandoz, the generic division of Novartis, is working with a local partner in Brazil which is undertaking the first clinical trial in that country for a biosimilar drug.
Interview with Mahesh P. Karande, Head of the Africa Cluster for Novartis. In this role, he is responsible for leading Novartis business activities in sub-Saharan Africa.
Novartis teams test combinations of targeted therapeutic agents to combat drug resistance in tumors.
Talk to any cancer researcher or doctor today and what you hear is wonder and hope.
Cambridge neighbors, NIBR and Harvard, further disrupt technology. Read how their alliance is accelerating drug discovery.
Novartis has joined forces with lymphoma experts in academia to hack into the genetics of a rare form of blood cancer known as mantle cell lymphoma (MCL).
When the average person thinks of cancer research, one word is likely to spring to mind: cure. Almost everyone who has ever lost a friend or loved one to the disease is hoping for a permanent, reliable cure for cancer. The sooner, the better.
Review the strategy and annual performance of Novartis and read letters from our Chairman and CEO.
This site is intended for a global audience.